Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bedford, TX
NPI
1558517193
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1615 Hospital Pkwy, Ste 202
Bedford, TX, 76022
Phone (301) 326-8646
Groups this clinician bills Medicare through
Medicare paid, 2024
$125K
2,015 services
Medicare patients, 2024
307
Average age 73
Drug cost, 2024
$2.1M
3,969 prescriptions
Company payments, 2025
$34K
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Madhuri Devdhar was code 99490 (chronic, principal, and transitional care management), 777 times for 113 patients. In total Madhuri Devdhar billed 2,015 services in 20 codes, and Medicare paid $125K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-02-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 777 | 113 | $49.25 | $38K |
| 99214 Office E&M - Established | Office | 525 | 232 | $87.44 | $46K |
| 95251 Test - Miscellaneous | Office | 165 | 59 | $25.69 | $4,238 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 108 | 102 | $12.91 | $1,394 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 106 | 62 | $37.64 | $3,990 |
| 99204 Office E&M - New | Office | 66 | 66 | $110.94 | $7,322 |
| 99215 Office E&M - Established | Office | 64 | 30 | $134.55 | $8,611 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 58 | 17 | $48.56 | $2,817 |
| 76536 Ultrasound - Nonspecific | Office | 37 | 37 | $80.03 | $2,961 |
| G0506 Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 33 | 32 | $47.74 | $1,575 |
| 99213 Office E&M - Established | Office | 20 | 18 | $62.87 | $1,257 |
| 99205 Office E&M - New | Office | 15 | 15 | $165.15 | $2,477 |
| 96372 Injection Administration | Office | 12 | 12 | $11.27 | $135 |
By year: 2022 $80K for 1,344 services; 2023 $97K for 1,499 services; 2024 $125K for 2,015 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 25 | 20 | $9.52 | $238 |
| 82962 Clinical Chemistry | 24 | 19 | $3.21 | $77.04 |
Medicare prescription drug claims, 2024
In 2024, the drug Madhuri Devdhar prescribed most often to Medicare patients was Metformin Hcl Er (Metformin Hcl), with 378 prescriptions and refills. In total Madhuri Devdhar wrote 3,969 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metformin Hcl Er Metformin Hcl | 378 | 952 | 126 | $5,068 |
| Levothyroxine Sodium Generic | 325 | 903 | 96 | $3,283 |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 280 | 633 | 85 | $476K |
| Ozempic Semaglutide | 185 | 315 | 52 | $296K |
| Glipizide Generic | 160 | 434 | 55 | $1,441 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 154 | 459 | 79 | $12K |
| Metformin Hcl Generic | 152 | 438 | 51 | $1,004 |
| Glimepiride Generic | 143 | 406 | 48 | $1,664 |
| Methimazole Generic | 128 | 339 | 40 | $1,577 |
| Jardiance Empagliflozin | 119 | 212 | 34 | $123K |
| Trulicity Dulaglutide | 103 | 193 | 27 | $190K |
| Mounjaro Tirzepatide | 99 | 137 | 23 | $143K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 92 | 222 | 35 | $21K |
| Glipizide Er Glipizide | 86 | 210 | 29 | $1,070 |
| Atorvastatin Calcium Generic | 77 | 224 | 28 | $725 |
Brand drugs: 1,767 claims; generic drugs: 1,899 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Madhuri Devdhar $34K ($34K in general payments such as food, travel and fees) from 35 companies. The largest payer was Abbott Laboratories with $27K.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 63 | $27K |
| Sanofi-Aventis U.S. LLC SNY | 8 | $3,214 |
| Medtronic, Inc. MDT | 29 | $1,311 |
| Amgen Inc. AMGN | 19 | $324 |
| Novo Nordisk Inc NVO | 11 | $281 |
| Neurocrine BioSciences, Inc. NBIX | 7 | $170 |
| Radius Health, Inc. | 4 | $91.35 |
| Insulet Corporation PODD | 4 | $81.6 |
| Corcept Therapeutics CORT | 3 | $76.97 |
| Mannkind Corporation MNKD | 3 | $72.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.